List view / Grid view
AstraZeneca will present new data from its pipeline of investigational…
29 September 2014 | By AstraZeneca
AstraZeneca will present new data from its pipeline of investigational cancer medicines over the next three days at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid...
AstraZeneca today announced that the US Food and Drug Administration…
26 June 2014 | By AstraZeneca
AstraZeneca today announced that the US Food and Drug Administration Oncologic Drugs Advisory Committee voted 11 to 2 that current evidence from clinical studies does not support an accelerated approval for use of olaparib...
New data from AstraZeneca’s investigational cancer medicines demonstrate the rapid…
15 May 2014 | By AstraZeneca
New data from AstraZeneca’s investigational cancer medicines demonstrate the rapid progression of its oncology pipeline...
Study evaluating novel investigational IL-17 receptor antibody meets all primary…
12 May 2014 | By AstraZeneca
Study evaluating novel investigational IL-17 receptor antibody meets all primary and secondary endpoints...
AstraZeneca announced that the US Food and Drug Administration has…
6 May 2014 | By AstraZeneca
AstraZeneca announced that the US Food and Drug Administration has approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridaemia...
AstraZeneca announced that the US Food and Drug Administration has…
3 March 2014 | By AstraZeneca
AstraZeneca announced that the US Food and Drug Administration has approved the BYDUREON® Pen 2 mg as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes...
AstraZeneca and Bristol-Myers Squibb Company announced the FDA approved FARXIGA™…
13 January 2014 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company announced the FDA approved FARXIGA™ (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus...
Lesinurad is an investigational agent being studied as a selective…
13 December 2013 | By AstraZeneca
Lesinurad is an investigational agent being studied as a selective uric acid re-absorption inhibitor that inhibits the URAT1 transporter...
SAVOR provides information on cardiovascular safety for Onglyza in the…
2 September 2013 | By AstraZeneca
SAVOR provides information on cardiovascular safety for Onglyza in the wake of past questions about cardiovascular safety of type 2 diabetes treatments...
AstraZeneca announced top-line results from OSKIRA-2 and OSKIRA-3...
4 June 2013 | By AstraZeneca
AstraZeneca announced top-line results from OSKIRA-2 and OSKIRA-3...
PATHOS a real-world retrospective study...
19 March 2013 | By AstraZeneca
PATHOS a real-world retrospective study...
AstraZeneca announced high-level results from KODIAC-08...
26 February 2013 | By AstraZeneca
AstraZeneca announced high-level results from KODIAC-08...
